Spinal Muscular Atrophy Type II: Clinical Trials

2 trials for Spinal Muscular Atrophy Type II, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Terminated 1
Phase 11Terminated 1

Follow Spinal Muscular Atrophy Type II: new trials by email Literature Review of Spinal Muscular Atrophy Type II trials Research Report on Spinal Muscular Atrophy Type II

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.
Olesoxime, Placebo - Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III Non Ambulant
Phase 2CompletedHoffmann-La Roche1652010-11-012016-11-22
Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III
sodium phenylbutyrate - Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III
Phase 1 / Phase 2TerminatedWestat92008-01-012010-09-08

Narrower conditions

Spinal Muscular Atrophies of Childhood (2)  ·  Motor Neuron Disease (1)  ·  Muscular Atrophy, Spinal (1)

Broader conditions

Central Nervous System Diseases (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Genetic Diseases, Inborn (2)  ·  Heredodegenerative Disorders, Nervous System (2)  ·  Nervous System Diseases (2)  ·  Neurodegenerative Diseases (2)  ·  Neuromuscular Diseases (2)  ·  Spinal Cord Diseases (2)  ·  Motor Neuron Disease (1)  ·  Muscular Atrophy, Spinal (1)

Interventions

4-phenylbutyric acid (1)  ·  olesoxime (1)

Sponsors

Hoffmann-La Roche (1)  ·  Westat (1)

Countries

Belgium (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Enrico Bertini, MD (1)  ·  Peter R. Gilbert, ScM (1)

Results publications

PMID 28460889

NIH funding

N01NS42361 (1)